English | 简体中文 | 繁體中文 | 한국어
 All Press Releases
 Medicine Healthcare & Pharm
CMS (867.HK/8A8.SG): Innovative Drug Oral JAK1 Inhibitor Povorcitinib Has Been Included in the List of Breakthrough Therapeutic Drugs in China
Dec 15, 2025 21:00 HKT
雲頂新耀發佈2030戰略規劃 管理層及主要股東增持超3800萬港元股份
Dec 15, 2025 16:59 HKT
云顶新耀发布2030战略规划 管理层及主要股东增持超3800万港元股份
Dec 15, 2025 16:59 HKT
Everest Medicines Unveils 2030 Strategy as Directors and Substantial Shareholder Buy Over HKD 38 Million of Shares
Dec 15, 2025 16:59 HKT
国资护航+技术壁垒+优质保荐 华芢生物(02396.HK)PDGF管线直指18A赛道确定性价值
Dec 15, 2025 11:05 HKT
國資護航+技術壁壘+優質保薦 華芢生物(02396.HK)PDGF管線直指18A賽道確定性價值
Dec 15, 2025 09:28 HKT
Everest Medicines Announces Commercialization Service Agreement and License Agreement with Hasten
Dec 12, 2025 14:35 HKT
云顶新耀与海森生物签署商业化服务协议及授权许可协议 推动商业化协同与多领域布局
Dec 12, 2025 14:35 HKT
雲頂新耀與海森生物簽署商業化服務協議及授權許可協議 推動商業化協同與多領域佈局
Dec 12, 2025 14:35 HKT
康哲藥業(0867)抗急性缺血性卒中創新藥注射用Y-3中國NDA獲受理
Dec 11, 2025 20:01 HKT
CMS (867/8A8): NDA of Innovative Drug Y-3 for Injection for Acute Ischemic Stroke Accepted in China
Dec 11, 2025 20:00 HKT
康哲药业(0867)抗急性缺血性卒中创新药注射用Y-3中国NDA获受理
Dec 11, 2025 19:53 HKT
拨康视云股价飙升逾8成 多重利好催化迎价值重估
Dec 11, 2025 08:20 HKT
Cloudbreak Pharma Soars 80%+ on Multiple Catalysts, Driving Value Re-Rating
Dec 11, 2025 08:20 HKT
撥康視雲股價飆升逾8成 多重利好催化迎價值重估
Dec 11, 2025 08:20 HKT
GEN Announces New Positive Phase 1 Trial Data of the Investigational Drug SUL-238 for Alzheimer's and Other Neurodegenerative Diseases
Dec 02, 2025 13:00 HKT
GEN 宣布针对阿尔茨海默病及其他神经退行性疾病的试验性药物 SUL-238 取得新的积极 I 期临床试验数据
Dec 02, 2025 13:00 HKT
GEN 宣布針對阿茲海默症及其他神經退化性疾病之試驗藥物 SUL-238 取得全新第一期試驗正面數據
Dec 02, 2025 13:00 HKT
AdipoLABs Opens New Regional Office, Signs Two MoUs With University of Cyberjaya to Advance Healthcare Innovation
Dec 02, 2025 12:22 HKT
君聖泰醫藥公佈HTD1801與達格列淨的頭對頭III期臨床研究結果 展現控糖優勢及心血管代謝優效獲益
Dec 02, 2025 10:59 HKT
Next >>
Copyright © 2025 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: